BridgeBio Pharma Inc. has announced that it will present Phase 2 proof-of-concept data for the drug Encaleret in treating post-surgical hypoparathyroidism at the upcoming American Society for Bone and Mineral Research (ASBMR) Annual Meeting 2025. The presentation, led by Dr. Iris Hartley from the National Institute of Dental and Craniofacial Research, is scheduled for September 6, 2025. In addition, BridgeBio will share findings from two poster sessions on skeletal dysplasia, highlighting the efficacy of Infigratinib in improving bone growth and skull measures in mouse models. These sessions will be presented by Bhavik Shah, Ph.D., Senior Vice President of Research at BridgeBio, on September 5 and 7, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9520679-en) on September 02, 2025, and is solely responsible for the information contained therein.